Oncology NEWS International Vol 12 No 11

Letrozole After Tamoxifen Cuts Breast Ca Recurrence

November 01, 2003

TORONTO-Postmenopausal women with early-stage breast cancer who took the aromatase inhibitor letrozole (Femara) after completing 5 years of tamoxifen therapy had a 43% lower risk of recurrence than those receiving placebo, an international phase III clinical trial has found.

Docetaxel Bests Paclitaxel in Metastatic Breast Cancer

November 01, 2003

COPENHAGEN, Denmark-In the first head-to-head comparison of the two taxanes, docetaxel (Taxotere) produced significantly longer survival in patients with metastatic breast cancer, compared with paclitaxel (Taxol), but at the cost of increased toxicity. Peter Ravdin, MD, PhD, clinical professor of medicine, The University of Texas Health Science Center, San Antonio, and principal investigator of the study, presented the phase III findings at ECCO 12, the European Cancer Conference (abstract 670). The study was sponsored by Aventis, manufacturer of Taxotere.

Advances in Treatment of Non–Small-Cell Lung Cancer

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

ATAC Data Ease Concerns About Risk of Bone Fractures

November 01, 2003

COPENHAGEN, Denmark-The risk and incidence of bone fractures associated with the use of the aromatase inhibitor anastrozole (Arimidex) for treatment of early breast cancer in postmenopausal women appears to stabilize after peaking at 2 years, easing some of the major concerns about the drug.

Alcohol Use & Weight Modifiable Breast Ca Risk Factors

November 01, 2003

CHICAGO-A large body of epidemiological literature has identified a number of breast cancer risk factors that are not considered modifiable, Susan Gapstur, PhD, said at the Fifth Annual Lynn Sage Breast Cancer Symposium. These include family history of breast cancer, age, personal history of atypia, hormone levels and hormonally related factors such as dense breasts, age of first childbearing, and age at menopause.

Docetaxel–HER1/EGFR Drug Combo Is Promising in Recurrent NSCLC

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

FDA Approves New Taxotere Indication as First-Line Therapy for NSCLC

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Nonplatinum Doublet Vinorelbine/ Gemcitabine Effective in NSCLC

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Erlotinib Plus Bevacizumab Combination Safe and Promising Against NSCLC

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Novel Apoptosis-Inducing Agents Entering Phase I Trials

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

New Targeted Therapies: Recognizing and Managing Toxicities

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Surgery After CT/RT in NSCLC: Benefits Upheld With Longer Follow-up of Intergroup 0139

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Gemcitabine Regimens Significantly Improve Advanced NSCLC

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Iressa Approved for Advanced NSCLC

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Cetuximab/Docetaxel Combination Shows Promise Against Advanced Non–Small-Cell Lung Cancer

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Pemetrexed Equivalent to Docetaxel for Recurrent NSCLC Patients

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Adding Cetuximab to Cisplatin/Vinorelbine Raises Response Rate in Phase II NSCLC Trial

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

With Cetuximab and Erlotinib, Rash Correlates With Survival

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Multidisciplinary Approach Improves Staging of NSCLC

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Newer Combination Therapies and Targets Reported for Advanced NSCLC

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Early Intervention With Epoetin Prevents Anemia in NSCLC Patients

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.

Adjuvant Chemo Might Prevent 7,000 NSCLC Deaths Worldwide Each Year

November 01, 2003

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2003, asreported in ONI. Guest editor Dr. Roy Herbst comments on the reports includedherein and discusses advances in the clinical management of lung cancer, with afocus on developments in targeted therapy, new combinations, adjuvant therapy,induction therapy, and what to watch for in 2004.